Lupin Limited is an Indian multinational pharmaceutical company and one of the largest generic pharmaceutical companies by revenue globally. Headquartered in Mumbai, India, Lupin is a significant player in the U.S., India, and Japan, along with other regulated and emerging markets. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs across various therapeutic areas including cardiovascular, diabetology, asthma, pediatrics, CNS, GI, anti-infective, and NSAIDs. Lupin is committed to providing affordable healthcare solutions worldwide and is increasingly focusing on complex generics and specialty pharmaceuticals.
Serves as the central hub for global strategic decision-making, corporate governance, R&D oversight, and management of worldwide operations.
Located in Kalpataru Inspire, a LEED Gold certified building, reflecting a modern and sustainable workspace in a prime business district of Mumbai.
Lupin fosters a culture centered around its core values of CARE: Customer focus, Achieving excellence, Respect for people, and Ethics & Integrity. It emphasizes innovation, collaboration, and an entrepreneurial spirit among its diverse global workforce.
The Mumbai headquarters is pivotal for Lupin's identity as a major Indian multinational, coordinating its extensive R&D, manufacturing, and commercial operations across more than 100 countries.
Lupin has a robust global presence, with operations in over 100 countries. Key functions supported globally include research and development, state-of-the-art manufacturing of APIs and formulations, quality control, regulatory affairs, and extensive marketing and distribution networks. The company has a significant footprint in markets like India, the United States, Japan, Europe, Latin America, Australia, and South Africa, with multiple manufacturing plants and R&D centers strategically located worldwide.
Kalpataru Inspire, 3rd Floor, Off Western Express Highway, Santacruz (East)
Mumbai
Maharashtra
India
Address: Harborplace Tower, 111 S. Calvert Street, Suite 1550, Baltimore, MD 21202, USA
Manages and supports Lupin's significant presence in the United States, which is one of its largest markets for generic and specialty pharmaceuticals.
Address: Various facilities including 400 Campus Drive, Somerset, NJ 08873, USA
Drives pharmaceutical innovation, product development, and manufacturing to supply the U.S. market and support Lupin's global product pipeline.
Address: Dammstrasse 19, 6300 Zug, Switzerland
Facilitates market access, commercial operations, and business development within the European Union and other European markets.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Lupin Pharmaceuticals' leadership includes:
Lupin Pharmaceuticals has been backed by several prominent investors over the years, including:
Lupin Pharmaceuticals has experienced significant leadership updates in the past year, most notably the appointment of a new Chief Financial Officer, Christoph Funke, who succeeded Ramesh Swaminathan. The company also strengthened its API business leadership with the appointment of Dr. Shahin Fesharaki.
Discover the tools Lupin Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Lupin Pharmaceuticals primarily uses the [first][last]@lupin.com email format. Other variations might exist but this is reported as the most common.
[first][last]@lupin.com
Format
janedoe@lupin.com
Example
75%
Success rate
Lupin Official Website / BSE India • May 8, 2024
Lupin Limited announced its audited financial results for the fourth quarter and full financial year ending March 31, 2024, highlighting key performance indicators, revenue growth, and profitability metrics....more
Lupin Official Website / FDA News • May 2, 2024
Lupin announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Bromfenac Ophthalmic Solution, 0.07%, a generic equivalent of BromSite® Ophthalmic Solution, 0.075%, of Sun Pharmaceutical Industries Limited....more
Lupin Official Website / FDA News • April 22, 2024
Lupin received approval from the U.S. FDA for its ANDA for Mirabegron Extended-Release Tablets, USP, 25 mg and 50 mg, a generic equivalent of Myrbetriq® Extended-Release Tablets of Astellas Pharma Global Development, Inc. This product will be manufactured at Lupin’s Pithampur facility in India....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Lupin Pharmaceuticals, are just a search away.